home / stock / phio / phio news

PHIO News and Press, Phio Pharmaceuticals Corp. From 12/06/23

Stock Information
Company Name: Phio Pharmaceuticals Corp.
Stock Symbol: PHIO
Market: NASDAQ
Website: phiopharma.com
Menu
PHIO PHIO Quote PHIO Short PHIO News PHIO Articles PHIO Message Board
Get PHIO Alerts

News, Short Squeeze, Breakout and More Instantly...
PHIO - TGTX, IBIO and ALT are among pre market gainers

2023-12-06 08:32:51 ET MicroAlgo ( MLGO ) +57% announced plans to establish a practice base to train graduate students for the university Pharvaris ( PHVS ) +38% surges on mid-stage success for hereditary angioedema therapy. ZyVersa Therapeutics  ( ZVSA ...
PHIO - Penny Stocks To Buy Now? 5 Under $5 To Watch This Week

2023-12-05 17:10:33 ET Penny stocks , defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it’s understandable why penny stocks attract interest from new traders. However, diving into penny...

PHIO - Phio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29

2023-11-09 18:04:13 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals For further details see: Phio Pharmaceuticals ...

PHIO - Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial r...
PHIO - Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first...

PHIO - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

PHIO - Expected earnings - Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (PHIO) is expected to report $-1.43 for Q3 2023
PHIO - Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the presentati...

PHIO - MNTS, WHLR and PHIO among pre-market losers

2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...

PHIO - JAGX, LGMK and FEMY among mid-day movers

2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
Previous 10 Next 10